Prevalence of Chemokine and Chemokine Receptor Polymorphisms in Seroprevalent Children with Symptomatic HIV-1 Infection in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 3, 2004, Pages 309-313

  Singh, Kumud K ^a   Barroga, Charlene F ^a   Hughes, Michael D ^c   Chen, Jie ^c   Raskino, Claire ^c   McKinney Jr , Ross E ^d   Spector, Stephen A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemokine receptors; Chemokines; Children; HIV 1; Polymorphisms; Race ethnicity

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CAUCASIAN; CHILD; CLINICAL TRIAL; DISEASE COURSE; DISEASE TRANSMISSION; DNA POLYMORPHISM; ETHNOLOGY; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEGRO; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RACE; SEROPREVALENCE; UNITED STATES;

CHEMOKINES; CHILD; GENOTYPE; HIV INFECTIONS; HUMANS; RECEPTORS, CHEMOKINE; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES; VARIATION (GENETICS);

EID: 1442274957     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200403010-00013     Document Type: Article

References (28)

1. Kinter A, Arthos J, Cicala C, et al. Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol Rev. 2000;177:88-98.
2. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 co-receptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
3. O'Brien SJ, Nelson GW, Winkler CA, et al. Polygenic and multifactorial disease gene association in man: lessons from AIDS. Annu Rev Genet. 2000;34:563-591.
4. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-673.
5. Barroga CF, Raskino C, Fangon MC, et al. The CCR5Delta32 allele slows disease progression of human immunodeficiency virus 1-infected children receiving antiretroviral treatment. J Infect Dis. 2000;182:413-419.
6. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-1862.
7. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
8. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
9. Buseyne F, Janvier G, Teglas JP, et al. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. J Infect Dis. 1998;178:1019-1023.
10. Shearer WT, Kalish LA, Zimmerman PA. CCR5 HIV-1 vertical transmission. Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:180-181.
11. Misrahi M, Teglas JP, N'Go N, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA. 1998;279:277-280.
12. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870.
13. Easterbrook PJ, Rostron T, Ives N, et al. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect. Dis. 1999;180:1096-1105.
14. Kostrikis LG, Neumann AU, Thomson B, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol. 1999;73:10264-10271.
15. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998;4:350-353.
16. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science, 1997;277:959-965.
17. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-641, and SDF-1 3′ A Alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
18. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2 and SDF-1 variants on HIV-1 related disease progression and neurological impairment in children with symptomatic HIV-1 infection. J Infect Dis. 2003;188:1461-1472.
19. Englund JA, Baker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Pediatr Infect Dis J. 1996;15:1025-1036.
20. McKinney RE Jr, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. 1998; 133:500-508.
21. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.
22. Martinson JJ, Hong L, Karanicolas R, et al. Global distribution of the CCR2-641/CCR5-59653T HIV-1 disease-protective haplotype. AIDS. 2000;14:483-489.
23. Clark VJ, Metheny N, Dean M, et al. Statistical estimation and pedigree analysis of CCR2-CCR5 haplotypes. Hum Genet. 2001;108:484-493.
24. Williamson C, Loubser SA, Brice B, et al. Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations. AIDS. 2000;14:449-451.
25. John GC, Bird T, Overbaugh J, et al. CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. J Infect Dis. 2001;184:89-92.
26. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. Effects of CCR5-delta32 and CCR2-641 alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS. 2003;17:1631-1638.
27. Clegg AO, Ashton LJ, Biti RA, et al. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS. 2000;14:103-108.
28. Contopoulos-Ioannidis DG, O'Brien TR. Goedert JJ, et al. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J Acquir Immune Defic Syndr. 2003;32:70-76.